Deerfield Management buys 8% stake in manufacturer of custom hydrogels and wound dressings

Healthcare financier Deerfield Management took an 8% stake in wound care company Alliqua Biomedical, buying 1.875 million shares in response to the company's offering of 6.6 million additional shares on the Nasdaq for $4.55 apiece. Other investors, who weren't required to disclose their position right away, snapped up the remainder of shares, Alliqua said, adding that the underwriters exercised their 30-day option to purchase up to 989,011 additional shares of common stock.

Alliqua says its drug delivery hydrogels are differentiated because of the company's proprietary electron cross-linking process that converts the hydrogels into a solid formulation. Using an electron beam accelerator, the company says it can control the of amount polymer cross linking, obviate the need for chemical cross-linking agents and other impurities, and ensure high quality control.

Over-the-counter medications, skincare ingredients, wound healers and transdermal drug delivery patches all use Alliqua's hydrogel. Their active ingredients are embedded in the gel.

Hydrogel has several properties that make it a common material in all sorts of drug delivery experiments and activities. Those attributes include their hydrophilic (water-loving) nature, porous structure that can be "tuned" by changing the density of the crosslinks, ability to perform sustained release and physical flexibility.

Besides custom manufacturing, Alliqua also sells hydrogel-based wound dressings like the antimicrobial SilverSeal, as well as the Biovance allograft, which is derived from the placenta of a full-term human pregnancy. It was developed in partnership with Celgene ($CELG). The biotech owns 19% of Alliqua, but that was before the latest equity financing, which lasted from April 29 to May 4.

J. Goldman & Co LP and Broadfin Capital LLC also owned more than 7% of the company's shares.

Alliqua said it will use the money raised to fund expansion of its marketed products, add additional product platforms, and for working capital. It share trade around $4.80, down from around $5 when the follow-on financing was announced.

- read the release
- read the SEC filing showing Deerfield's acquisition

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.